UK Biobank is a population-based cohort of half a million participants aged 40–69 years
recruited between 2006 and 2010. In 2014, UK Biobank started the world's largest multi …

The prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing worldwide. In
some patients with NAFLD, isolated steatosis can progress to advanced stages with non …

Initially a condition that received limited recognition and whose clinical impact was
controversial, non-alcoholic steatohepatitis (NASH) has become a leading cause of chronic …

Nonalcoholic fatty liver disease (NAFLD) affects 25% of the global adult population and is
the most common chronic liver disease worldwide. Nonalcoholic steatohepatitis (NASH) is …

The aim of this review is to outline emerging biomarkers that can serve as early diagnostic
tools to identify patients with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic …

Background & Aims Non-alcoholic steatohepatitis (NASH) is a chronic, progressive fibrotic
liver disease that can lead to cirrhosis. While liver biopsy is considered the reference …

Reversibility of hepatic fibrosis and cirrhosis following antiviral therapy for hepatitis B or C
has advanced the prospect of developing antifibrotic therapies for patients with chronic liver …

Understanding the molecular mechanisms underlying liver fibrogenesis is fundamentally
relevant to developing new treatments that are independent of the underlying etiology. The …

Nonalcoholic fatty liver disease (NAFLD) is the most common cause of liver dysfunction in
the Western world and is increasing owing to its close association with obesity and insulin …

With the increasing number of individuals with diabetes and obesity, nonalcoholic fatty liver
disease (NAFLD) is becoming increasingly prevalent, affecting one-quarter of adults …